Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash from Financing Activities (2019 - 2023)

Historic Cash from Financing Activities for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to -$1000.0.

  • ADC Therapeutics' Cash from Financing Activities rose 9988.87% to -$1000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $73.9 million, marking a year-over-year increase of 833578.6%. This contributed to the annual value of $97.1 million for FY2024, which is 3137.6% up from last year.
  • ADC Therapeutics' Cash from Financing Activities amounted to -$1000.0 in Q4 2023, which was up 9988.87% from $349000.0 recorded in Q3 2023.
  • Over the past 5 years, ADC Therapeutics' Cash from Financing Activities peaked at $73.1 million during Q2 2023, and registered a low of -$898855.0 during Q4 2022.
  • For the 5-year period, ADC Therapeutics' Cash from Financing Activities averaged around $4.9 million, with its median value being -$252.0 (2022).
  • Per our database at Business Quant, ADC Therapeutics' Cash from Financing Activities tumbled by 7369761.9% in 2022 and then surged by 2900883015.87% in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' Cash from Financing Activities stood at -$129.0 in 2019, then plummeted by 215403.88% to -$278000.0 in 2020, then soared by 99.56% to -$1218.0 in 2021, then plummeted by 73697.62% to -$898855.0 in 2022, then soared by 99.89% to -$1000.0 in 2023.
  • Its Cash from Financing Activities was -$1000.0 in Q4 2023, compared to $349000.0 in Q3 2023 and $73.1 million in Q2 2023.